Showing results (71-80 of 82) with videos related to
Sort By:
Pageof 9
Haematologica|November 13, 2025
A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG studyRebeca Rodríguez-Veiga, Cristina Gil, Marta Sobas, et al.Transplantation and Cellular Therapy|April 10, 2021
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA StudyEduardo Rodríguez-Arbolí, David Martínez-Cuadrón, Rebeca Rodríguez-Veiga, et al.American Journal of Hematology|November 22, 2025
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 PatientsMatteo Molica, Gema Miralles, Richard Dillon, et al.Cancers|June 10, 2022
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaDavid Martínez-Cuadrón, Josefina Serrano, José Mariz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2025
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO TrialUwe Platzbecker, Lionel Adès, Pau Montesinos, et al.Cancer|January 3, 2025
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry studyPilar Lloret-Madrid, Blanca Boluda, Joaquín Martínez-López, et al.Leukemia|September 1, 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registryAna Alfonso-Pierola, David Martinez-Cuadrón, Rebeca Rodríguez-Veiga, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2025
Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, et al.Leukemia & Lymphoma|July 22, 2021
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA groupTomás Palanques-Pastor, Juan Eduardo Megías-Vericat, Pilar Martínez, et al.Haematologica|May 14, 2026
Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI studyPilar Lloret-Madrid, Rebeca Rodríguez-Veiga, Juan Miguel Bergua, et al.Pageof 9